Antiemetic medication for prevention and treatment of chemotherapy induced nausea and vomiting in childhood

Phillips, Bob; Gopaul, Shireen; Light, Kate; Craig, Jean; Pizer, Barry

doi:10.1002/14651858.cd007786

Cited by 5 publications

(3 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, clinicians caring for children enrolled in the AALL0331 protocol were advised against the routine use of corticosteroids such as dexamethasone for antiemetic prophylaxis, and dexamethasone was not given as an antileukemic agent during consolidation. We, therefore, speculate that most children in our study did not receive optimal CINV prophylaxis during treatment with highly and moderately emetogenic chemotherapy and did not have effective antiemetics available at home to effectively treat breakthrough CINV …”

Section: Discussionmentioning

confidence: 96%

Anxiety, pain, and nausea during the treatment of standard‐risk childhood acute lymphoblastic leukemia: A prospective, longitudinal study from the Children's Oncology Group

Dupuis

Mitchell

et al. 2016

Cancer

View full text Add to dashboard Cite

BACKGROUND This prospective study describes the procedure-related anxiety, treatment-related anxiety, pain, and nausea experienced by children with standard-risk acute lymphoblastic leukemia (ALL) during the first year of treatment. METHODS This study was undertaken at 31 Children’s Oncology Group (COG) sites. Eligible children who were 2 to 9.99 years old were enrolled in a COG trial for patients with newly diagnosed standard-risk ALL from 2005 to 2009. Parents completed a demographic survey at the baseline and the Pediatric Quality of Life Inventory 3.0 Cancer Module (proxy version) and the General Functioning Scale of the Family Assessment Device 1, 6, and 12 months after the diagnosis. The association between patient-related (age, sex, ethnicity, and treatment), parent-related (marital status and education), and family-related factors (functioning, income, and size) and symptom scores was evaluated. RESULTS The mean scores for procedure-related anxiety, treatment-related anxiety, and pain improved during the first year of treatment (P < .0389). The mean nausea score was poorer 6 months after the diagnosis in comparison with the other assessments (P = .0085). A younger age at diagnosis was associated with significantly worse procedure-related anxiety (P = .004). An older age (P = .0002) and assignment to the intensified consolidation study arm (P = .02) were associated with significantly worse nausea. CONCLUSIONS Children with ALL experienced decreasing treatment-related anxiety, procedure-related anxiety, and pain during the first year of treatment. In comparison with scores at 1 and 12 months, nausea was worse 6 months after the diagnosis. Minimization of procedure-related anxiety in younger children and improved nausea control in older children and those receiving more intensified treatment should be prioritized.

show abstract

Section: Discussionmentioning

confidence: 96%

Anxiety, pain, and nausea during the treatment of standard‐risk childhood acute lymphoblastic leukemia: A prospective, longitudinal study from the Children's Oncology Group

Dupuis

Mitchell

et al. 2016

Cancer

View full text Add to dashboard Cite

show abstract

“…Hence, need alternative routes of administration like transdermal administration are needed as an alternative to conventional route. [6] Transdermal drug delivery system (TDDS) have therapeutic benefits such as sustained drug delivery for drugs with short half-lives, maintain steady plasma profile, so reduced systemic side-effects in potent drugs, reducing the typical dosing schedule to once or twice weekly also so improved patient compliance; and avoidance of the first-pass metabolism effect for drugs with poor oral bioavailability. [7] Alternatively TDD can be used in situations requiring minimal patient cooperation.…”

Section: Introductionmentioning

confidence: 99%

Formulation and development of industry feasible proniosomal transdermal drug delivery system of granisetron hydrochloride

Patil¹,

Pol²,

Puranik³

et al. 2015

Asian J Pharm

View full text Add to dashboard Cite

P roniosomes gel is semisolid liquid crystal products of nonionic surfactants, which converted into niosomes upon hydration. A proniosome based transdermal drug delivery system of granisetron hydrochloride (GRA HCL) developed by coacervation phase separation method. Formulation optimized by use of 3 2 full factorial design. Span 60 and cholesterol selected as independent variables, while entrapment efficiency (EE) and flux selected as dependent variables. Proniosomes evaluated for EE, in vitro permeation study, stability study, microscopial examination by photomicroscopy, scanning electron microscopy, particle size analysis. F5 batch containing 90 mg span 60, and 10 mg cholesterol show maximum entrapment (66.57 ± 0.20%) and flux (7.94 ± 0390 μg/cm 2 /h). Comparative in vitro drug release study of plain drug solution and drug in proniosomal gel form was carried out for 48 h on guinea pig skin. It was found that cumulative release and flux of proniosomal gel was nearly two times more than drug solution containing same drug concentration. The study demonstrated the effectiveness of proniosomal transdermal patch containing GRA HCL for effective management of chemotherapy induced nausea and vomiting.How to cite this article: Patil BA, Puranik PK, Pol SD, Khobragade PK, Ramteke PS, Palasakar RG, et al. Formulation and development of industry feasible proniosomal transdermal drug delivery system of granisetron hydrochloride. Asian J Pharm 2015;9:113-9.

show abstract

“…Although Western pediatric AML protocols no longer prescribe GCs as antileukemic agents, several low‐income countries still rely on them. Furthermore, GCs are globally being used for chemotherapy‐induced nausea and acute respiratory distress syndrome in children with AML. Lastly, GCs are being used frequently as intrathecal antileukemic agents.…”

Section: Discussionmentioning

confidence: 99%

Glucocorticoid-Induced Proliferation in Untreated Pediatric Acute Myeloid Leukemic Blasts

Klein

Haarman

Haas

et al. 2016

Pediatr Blood Cancer

View full text Add to dashboard Cite

We evaluated the in vitro glucocorticoid (GC) responsiveness of 117 pediatric acute myeloid leukemia cells by considering GC resistance, GC-induced proliferation, and GC-induced differentiation. None of the samples was highly GC sensitive, and only 15% were intermediately sensitive. GC-induced differentiation was not observed, while GC-induced proliferation was observed in 27% of the samples. Samples with French-American-British classification (FAB) type M5 or activating Fms-like tyrosine kinase 3 (FLT3) mutations were significantly more prone to this phenomenon. Although we could not confirm this in our study, if induced proliferation in vitro is paralleled in vivo, GCs during consolidation may have adverse effects on minimal residual leukemic cells, which might increase relapse risk.

show abstract

Antiemetic medication for prevention and treatment of chemotherapy induced nausea and vomiting in childhood

Cited by 5 publications

References 13 publications

Anxiety, pain, and nausea during the treatment of standard‐risk childhood acute lymphoblastic leukemia: A prospective, longitudinal study from the Children's Oncology Group

Anxiety, pain, and nausea during the treatment of standard‐risk childhood acute lymphoblastic leukemia: A prospective, longitudinal study from the Children's Oncology Group

Formulation and development of industry feasible proniosomal transdermal drug delivery system of granisetron hydrochloride

Glucocorticoid-Induced Proliferation in Untreated Pediatric Acute Myeloid Leukemic Blasts

Contact Info

Product

Resources

About